Adhatoda vasica rescues the hypoxia-dependent severe asthma symptoms and mitochondrial dysfunction

• Published in: American journal of physiology. Lung cellular and molecular physiology 2021-05, Vol.320 (5), p.L757-L769
• Main Authors: Gheware, Atish, Panda, Lipsa, Khanna, Kritika, Bhatraju, Naveen Kumar, Jain, Vaibhav, Sagar, Shakti, Kumar, Manish, Singh, Vijay Pal, Kannan, Sadasivam, Subramanian, Venkatesan, Mukerji, Mitali, Agrawal, Anurag, Prasher, Bhavana
• Format: Article
• Language: English
• Subjects: Allergic diseases; Animal models; Animals; Asthma; Asthma - drug therapy; Asthma - etiology; Asthma - metabolism; Asthma - pathology; Dexamethasone; Disease Models, Animal; Epithelial cells; Epithelium; Gene Expression Regulation; Glycosides; Homology; Hydroxylase; Hypoxia; Hypoxia - complications; Hypoxia-inducible factor 1a; Inflammation; Interleukin 6; Interleukin 8; Janus kinase; Justicia - chemistry; Kinases; Male; Mice; Mice, Inbred BALB C; Mitochondria; Mitochondria - drug effects; Mitochondria - metabolism; Mitochondria - pathology; Oral administration; Phytochemicals - pharmacology; Plant Extracts - pharmacology; Pneumonia - etiology; Pneumonia - metabolism; Pneumonia - pathology; Pneumonia - prevention & control; Prolyl hydroxylase; Respiratory tract diseases; Signs and symptoms; Steroids; Tumor necrosis factor-α
• ISSN: 1040-0605; 1522-1504
• DOI: 10.1152/ajplung.00511.2020

Severe asthma is a chronic airway disease that exhibits poor response to conventional asthma therapies. Growing evidence suggests that elevated hypoxia increases the severity of asthmatic inflammation among patients and in model systems. In this study, we elucidate the therapeutic effects and mechanistic basis of (AV) aqueous extract on mouse models of acute allergic as well as severe asthma subtypes at physiological, histopathological, and molecular levels. Oral administration of AV extract attenuates the increased airway resistance and inflammation in acute allergic asthmatic mice and alleviates the molecular signatures of steroid (dexamethasone) resistance like IL-17A, KC (murine IL-8 homologue), and HIF-1α (hypoxia-inducible factor-1α) in severe asthmatic mice. AV inhibits HIF-1α levels through restoration of expression of its negative regulator-PHD2 (prolyl hydroxylase domain-2). Alleviation of hypoxic response mediated by AV is further confirmed in the acute and severe asthma model. AV reverses cellular hypoxia-induced mitochondrial dysfunction in human bronchial epithelial cells-evident from bioenergetic profiles and morphological analysis of mitochondria. In silico docking of AV constituents reveal higher negative binding affinity for C and O-glycosides for HIF-1α, IL-6, Janus kinase 1/3, TNF-α, and TGF-β-key players of hypoxia inflammation. This study for the first time provides a molecular basis of action and effect of AV whole extract that is widely used in Ayurveda practice for diverse respiratory ailments. Further, through its effect on hypoxia-induced mitochondrial dysfunction, the study highlights its potential to treat severe steroid-resistant asthma.